Patients with myasthenia gravis (MG) largely expressed negative emotions around MG treatment and symptom burden in patient focus groups and on MG social media discussion boards.

Low-dose oral minoxidil has been agreed upon by an international expert panel as an effective treatment for various hair loss conditions, such as alopecia, with guidelines provided for safe and effective use.

This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions.

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).

President-elect Donald Trump will nominate heart surgeon turned television personality and politician Mehmet Oz, MD, also known as Dr Oz, to lead CMS.

Lowering the positivity threshold for a high-quality fecal immunochemical test (FIT) can increase sensitivity of noninvasive screening for colorectal cancer in a more economical way.

Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and psoriasis onset in US adults.

The new report from US Surgeon General Vivek H. Murthy, MD, MBA, highlights persistent disparities in tobacco use and secondhand smoke exposure, calling for equitable strategies to achieve a tobacco-free future.

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).

Results bring more competition to treat this genetically driven target for cardiovascular risk.

Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public health strategies.

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.

A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment for longer than anticipated.

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis of the elements of its composite end point.